On 20 April 2026, Luye Pharma Group Ltd. disclosed the enrolment of the first volunteer in a U.S. pharmacokinetic (PK) bridging trial for LY03015, the company’s in-house-developed new molecular entity designed as both a vesicular monoamine transporter 2 (VMAT2) inhibitor and a sigma-1 receptor (Sigma-1R) agonist. The compound targets tardive dyskinesia (TD) and Huntington’s disease (HD), marking the first global programme to combine these two mechanisms in a single investigational therapy.
LY03015 aims to control TD and HD symptoms by reducing presynaptic dopamine release through VMAT2 inhibition while potentially promoting synaptic remodeling via Sigma-1R activation. Preclinical rationale suggests this dual action could provide sustained symptom relief and lower recurrence after treatment discontinuation.
The ongoing study is an open-label, single-dose, parallel-group trial comparing healthy Chinese and Caucasian adults. Key endpoints include safety, tolerability, and PK parameters, which will inform dose selection for planned Phase II and Phase III trials in the United States. A separate Phase II study in China is nearing completion.
Clinical demand remains significant: approximately 25.30% of patients on antipsychotic therapy develop TD, and 67.00%–89.00% of these individuals experience permanent involuntary movements. HD, an autosomal dominant neurodegenerative disorder, also lacks curative therapies. To date, VMAT2 inhibitors are the only class approved by the U.S. FDA for both indications, underscoring the therapeutic gap LY03015 seeks to address.
Central nervous system (CNS) therapeutics are a strategic priority for Luye Pharma. Commercially, the group markets Erzofri (paliperidone palmitate extended-release injectable), Rykindo (risperidone extended-release injectable), the Rivastigmine Twice Weekly Transdermal Patch, and Ruoxinlin (toludesvenlafaxine sustained-release tablets). Investigational assets include LY03017 (5-HT2AR/5-HT2CR), LY03020 (TAAR1/5-HT2CR), and LY03021 (GABAAR/NET/DAT).
Luye Pharma intends to accelerate development of LY03015 in both China and the United States to strengthen its competitive position in the VMAT2 inhibitor segment and, more broadly, the CNS therapeutic landscape.
Comments